MIRA Pharmaceutical shares are trading higher after the company's new preclinical data showed that Ketamir-2 achieved 60% greater efficacy than the FDA-approved gabapentin in reducing chemotherapy-induced pain.
Portfolio Pulse from Benzinga Newsdesk
MIRA Pharmaceutical's shares are rising following the release of preclinical data indicating that their drug, Ketamir-2, is 60% more effective than gabapentin in alleviating chemotherapy-induced pain.
October 28, 2024 | 11:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MIRA Pharmaceutical's stock is experiencing an upward trend due to promising preclinical results for Ketamir-2, which demonstrated superior efficacy over gabapentin in managing chemotherapy-induced pain.
The significant improvement in efficacy of Ketamir-2 over an FDA-approved drug like gabapentin is a positive development for MIRA Pharmaceutical. This could lead to increased investor confidence and potential future revenue streams if the drug progresses successfully through clinical trials.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100